These initial results provide a foundation for deeper improvements that continue as cellular turnover advances
Strang JF, Kenworthy L, Dominska A, Sokoloff J, Kenealy LE, Berl M, Walsh K, Menvielle E, Slesaransky-Poe G, Kim KE, Luong-Tran C, Meagher H, Wallace GL
Skin may appear more hydrated, with finer lines showing subtle softening
The agency flagged three adverse events in its FAERS database tied to compounded injectable BPC-157, including a case in which a patient developed diffuse hyperpigmentation and gingival darkening after using a blended BPC-157/TB-500 product labeled "research purposes only." The safety concern most specific to BPC-157 is its mechanism of action
Anti-VEGF drugs mechanistically oppose BPC-157's primary angiogenic action (VEGF upregulation)